Jump to Navigation

User login

Facebook Connect

NLA Meetings

Meeting Info

NLA Scientific Sessions 2014

Orlando, FL

New Era in Lipidology: Familial Hypercholesterolemia, Guidelines and Risk Assessment in the Clinic

Special Education Session at the Orlando 2014 Annual Scientific Sessions:
 
The National Lipid Association Recommendations for
Patient-Centered Management of Dyslipidemia

Friday, May 2 • 6:45 – 7:45 a.m.

As you know, the American College of Cardiology and the American Heart Association last fall released the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. The NLA found the document to be an important milestone and constructive in the care of patients but that it left several gaps to be addressed... Read more.

 
 Participate in the NLA Scientific Sessions Twitter Photo contest
 

This year the National Lipid Association will be hosting its first-ever Twitter photo contest during the NLA Scientific Sessions in Orlando! To participate, you’ll need a Twitter account (so join Twitter if you haven’t already — and if you haven’t, why haven’t you?) and follow the NLA Twitter feed @nationallipid.

Click Here for Complete Contest Rules


Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advanced practice registered nurses, and registered dietitians with an interest in lipid management.
 

This program is supported in part by the American Heart Association’s Councils on Clinical Cardiology, Epidemiology and Prevention, and Nutrition, Physical Activity and Metabolism.”

Type of Activity
Live Activity

You can view NLA Meeting Highlights from previous conferences.

Pre-Conference Courses:
Venue:
Hyatt Regency Grand Cypress Hotel

One Grand Cypress Blvd., Orlando, FL 32836

For reservations, please call 1-888-421-1442 and ask for the National Lipid Association room rate. A special room rate starting at $189 per night plus tax has been arranged. The rate is available until April 9, 2014, or until the room block is filled.  Please make your reservation early as we do anticipate that the room block will sell out.

About the Hotel

Enjoy being secluded in the heart of it all. Hyatt Regency Grand Cypress is unique among hotels in Orlando. Both a grand luxury hotel and a spectacular meeting facility, it offers the best of everything; a secluded setting, superior service, diverse dining options, exclusive amenities and an ideal location in the heart of the most popular Orlando theme parks. With its own private lake, enhanced lagoon pool, golf, and miles of tropical nature trails for bicycling and jogging, this landmark hotel allows guests to experience both the ultimate in luxury, as well as a convenient location close to Orlando’s most popular theme parks, and dining and entertainment venues. To learn more about the hotel, please visit grandcypress.hyatt.com/en/hotel/home.html.

make your hotel reservation

 

Thursday, May 1, 2014

Session I- Familial Hypercholesterolemia- Diagnosis and Treatment Options

3:40 - 4:00 PM Welcome & Introductions Matthew K. Ito, PharmD, FNLA Ralph La Forge, MSc, CLS, FNLA
4:00 - 4:45 PM Keynote: History of PCSK9 from Discovery to Drug Development

Jonathan C. Cohen, PhD

4:45 - 4:55 PM Q&A Session
4:55 - 5:40 PM HoFH and HeFH: Definition and Diagnosis

Raul Santos, MD, PhD

5:40 - 5:50 PM Q&A Session
6:00 - 7:00 PM Welcome Reception in Exhibit Hall

Friday, May 2, 2014

Special Education Session

6:45 - 7:45 AM National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia NLA Expert Panel

Session II- Primer on Genetic Testing for FH

7:00 - 8:00 AM Breakfast in Exhibit Hall
7:45 - 8:05 AM SELA Business Meeting & Morning Notes
8:05 - 8:30 AM Using Genetic Tests Critically in Clinical Practice

Christie Ballantyne, MD, FNLA

8:30 - 8:55 AM Role of Genetic Counseling in FH: What Referring Physicians and Patients Need to Know

Amy Sturm, MS, LGC

8:55 - 9:25 AM Q&A Session
9:25 - 9:40 AM SWLA Business Meeting
9:40 - 10:10 AM Break in Exhibit Hall

Session III- Cascade Screening

10:10 - 10:35 AM Cascade Screening the Netherlands Experience

Joep C. Defesche, PhD

10:35 - 11:00 AM Cascade Screening for FH- the U.S. Experience

Paul N. Hopkins, MD

11:00 - 11:20 AM Q&A Panel
11:20 - 11:35 AM NELA Business Meeting
11:35 - 12:35 Lunch in Exhibit Hall
12:35 - 1:35 PM Oral Poster Presentations

Session IV- Non- Invasive Testing for Subclinical Atherosclerosis in FH and Issues in Women with FH

1:35 - 2:00 PM Screening for Heart Disease in 2014: Guidelines & Updates

Matthew J. Budoff, MD

2:00 - 2:25 PM Carotid Intima Media Thickness: A Practical How-to-Primer

Allen J. Taylor, MD

2:25 - 2:50 PM Non-Invasive Testing for Subclinical Atherosclerosis in FH- Coronary CTA

Michael Shapiro, DO

2:50 - 3:15 PM Women with Familial Hypercholesterolemia during Pregnancy

James A. Underberg, MD, MS, FNLA

3:15 - 3:40 PM Q&A Panel
3:40 - 3:55 PM Break

Session V- LDL Apheresis

3:55 - 4:25 PM Practical Aspects of Starting an LDL Apheresis Unit

Linda C. Hemphill, MD, FNLA

4:25 - 4:55 PM LP(a) as a Target

Patrick M. Moriarty, MD, FNLA

4:55 - 5:25 PM Adherence and Insurance Issues

Joyce L. Ross, MSN, ANP, FNLA

5:25 - 5:55 PM Q&A Panel

Saturday, May 3, 2014

Session VI- Statin Intolerance

7:00 - 8:00 AM Breakfast in Exhibit Hall
7:45 - 8:00 AM MWLA Business Meeting and Morning Notes
8:00 - 8:25 AM Muscle- Related Issues

Terry A. Jacobson, MD, FNLA

8:25 - 8:50 AM Primer on Drug-Statin Interaction

Matthew K. Ito, PharmD, FNLA

8:50 - 9:15 AM Effects of Statins on Exercise- Performance Exercise

Paul D. Thompson, MD

9:15 - 9:30 AM Q&A Panel
9:30 - 9:45 AM PLA Business Meeting
9:45 - 10:15 AM Break in Exhibit Hall

Session VII- Lipid Lowering Therapies in Clinical Practice

10:15 - 10:35 AM Antisense Therapy: A New Concept in Disease Management

P. Barton Duell, MD

10:35 - 10:55 AM The Role of Microsomal Triglyceride Transfer Protein (MTP) Inhibition on the Management of HoFH

Pamela B. Morris, MD, FNLA

10:55 - 11:15 AM Practical Nutrition Recommendations to Reduce GI ADRs to MTP Inhibitors

Mary N. Felando, RD, MS, FNLA

11:15 - 11:30 AM Q&A Panel
11:30 - 12:00 NLA/ FNLA Business Meeting
12:00 - 1:00 PM Lunch in Exhibit Hall

Session VIII- Combination Pharmacotherapy and Emerging Therapies

1:00 - 1:25 PM Combination Therapy for Familial Hypercholesterolemia

Anne C. Goldberg, MD, FNLA

1:25 - 1:50 PM Clinical Trials of PCSK9

James M. McKenney, PharmD, FNLA

1:50 - 2:05 PM Q&A Panel

Session IX- Contemporary Issues in Pediatric FH

2:05 - 2:30 PM Trials and Tribulations of Statin Use in Children

Brian W. McCrindle, MD, MPH

2:30 - 2:55 PM Primordial Prevention: Preserving Healthy Lipids Through Childhood

Darwin R. Labarthe, MD, MPH, PhD

2:55 - 3:20 PM International Guidance on the Management of Familial Hypercholesterolemia in Children

Gerald F. Watts, DSc, PhD, MD

3:20 - 3:35 PM Q&A Panel

Session X- Cardiac Rehabilitation, Physical Activity, and Exercise Testing in FH

3:35 - 4:00 PM Exercise Testing Guidelines for Patients with Familial Hypercholesterolemia

Ralph La Forge, MSc, CLS, FNLA

4:00 - 4:25 PM Update on Cardiac Rehabilitation

Vera A. Bittner, MD, MSPH, FNLA

4:25 - 4:40 PM Q&A Panel
4:40 - 5:00 PM Break

Session XI: Roundtable: Guidelines in Clinical Lipidology: The Essential Components

5:00 - 5:02 PM Introductions

W. Virgil Brown, MD, FNLA

5:02 - 5:17 PM Perspectives on the New Guidelines from the American College of Cardiology and the American Heart Association

Neil J. Stone, MD, FNLA*

5:17 - 5:32 PM An IAS Position Paper: Global Recommendations for the Management of Dyslipidemia

Scott M. Grundy, MD, PhD, FNLA*

5:32 - 5:47 PM Questions from the Chair

W. Virgil Brown, MD, FNLA

5:47 - 6:00 PM Q&A Panel

Sunday, May 4, 2014

8:00 - 9:00 AM Non-CME: An Invitation to Publish in the JCL W. Virgil Brown, MD, FNLA

Session XII- Getting Patients to Goal

9:00 - 9:05 AM Morning Notes
9:05 - 9:40 AM The Potential for Health Information Technology (HIT) to Enhance Lipid Goal Achievement

Jerome D. Cohen, MD, FNLA

9:40 - 9:50 AM Q&A Session
9:50 - 10:15 AM Cardio-Protective Diet for Familial Hypercholesterolemia

Lori A. Alexander, MSHS, RD, FNLA

10:15 - 10:40 AM Familial Hypercholesterolemia- Case Studies

Paul E. Ziajka, MD, PhD, FNLA

10:40 - 11:05 AM Management Crossroads in the Patient with Homozygus FH

Carl E. Orringer, MD, FNLA

11:05 - 11:30 AM Q&A Panel

Upon completion of the educational activity, participants should be able to:

Educational Objectives

At the conclusion of this activity, all participants should be able to:

Session I: Familial Hypercholesterolemia – Diagnosis and Treatment Options

  • Review the history PCSK9 from discovery to drug development
  • Define familial hypercholesterolemia (FH)
  • Describe the prevalence and associated risk, in order to increase awareness and understanding of the disease
  • Compare  Simon-Broome criteria, the Dutch Lipid Clinic criteria, and MEDPED in the diagnosis of FH

Session II: Primer on Genetic Testing for FH

  • Describe the current and future technologies available for genetic FH screening
  • Apply screening technologies in clinical practice with an emphasis on FH
  • Explain the role of the genetic counselor in screening for familial lipid disorders

Session III: Cascade Screening

  • Illustrate the importance of universal screening during childhood including the role of  cascade lipid screening of family members of known FH patients
  • Compare  screening recommendations in various populations
  • Employ these screening strategies in clinical practice

Session IV: Non-Invasive Testing for Subclinical Atherosclerosis in FH and Issues in Women with FH

  • Review the role of coronary CT angiography in cardiovascular disease risk assessment and management in asymptomatic FH patients
  • Identify the potential contribution of carotid IMT to cardiovascular risk assessment in asymptomatic FH patients
  • Review the use of newer imaging modalities for screening and preventing coronary artery disease
  • Review strategies for managing CVD risk in pregnant women or women who plan to become pregnant

Session V: LDL Apheresis

  • Describe the various practical  aspects of starting and maintaining a LDL Apheresis service
  • Review the business and personnel issues that impact a successful LDL Apheresis service
  • Identify the new evidence that Lp(a) has a potential pro-inflammatory role as a cardiovascular pathogen
  • Discuss patient stratification for disease management of FH patients with elevated Lp(a)
  • Implement effective communication and counseling strategies to educate your patients about current evidence-based medicine in order to support their efforts at self-management and adherence to therapies
  • Identify strategies to overcome real-world barriers (e.g., lack of insurance coverage, poor health literacy, cultural differences and suboptimal patient-physician interactions) to optimizing the management of Cardiometabolic disease in diverse populations

Session VI: Statin Intolerance

  •  Implement appropriate assessment and management techniques for muscle-related adverse events associated with lipid-altering drugs
  • Review the mechanism of statin-drug interactions including the impact on statin induced muscle side effects
  • Describe the effects of statins on muscle strength or exercise performance

Session VII: Lipid Lowering Therapies in Clinical Practice

  • Evaluate the clinical data for Antisens ApoB Oligonucleotide inhibitors including the effects, safety and efficacy for FH patients
  • Evaluate the clinical data for Microsomal Triglyceride Transfer Protein (MTP) Inhibitors including the effects, safety and efficacy data for FH patients
  • Discuss practical nutrient intake and food choices to minimize gastrointestinal adverse drug reactions to MTP Inhibitors

Session VIII: Combination Pharmacotherapy and Emerging Therapies

  • Assess the data on safety and efficacy of therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9) to provide additional lipid lowering benefits
  • Identify which interventions, including lifestyle changes and various drugs in combination, are most appropriate for  patients with FH based on their risk profiles

Session IX: Contemporary Issues in Pediatric FH

  • Discuss universal lipid screening and other strategies in children in reducing cardiovascular risk
  • Discuss current literature regarding statin medications in terms of efficacy and safety in children
  • Appraise treatment recommendations and evidence for screening, diagnosing and treating FH in children

Session X: Cardiac Rehabilitation, Physical Activity, and Exercise Testing in FH

  • Review the role of various types of physical activity on dyslipidemia and cardiovascular risk including the current status of cardiac rehabilitation
  • Recognize exercise testing recommendations in patients with FH
  • Define physical activity assessment and exercise testing protocols in FH

Session XI: Round Table: Guidelines in Clinical Lipidology: The Essential Components

  • Outline current dyslipidemia patient guidelines on the diagnosis, management and treatment
  • Apply guidelines into daily practice to help patients reach goals

Session XII: Getting Patients to Goal

  • Discuss the potential role of health information technology in optimizing lipid management
  • Utilize effective diet and lifestyle strategies for dyslipidemia management
  • Discuss the challenges of diagnosis and management of familial hypercholesterolemia
  • Analyze lipid cases for health professionals seeing patients with complex disorders
  • Discuss treatment strategies for special populations via case study presentations

 

CME credit provided by the National Lipid Association

Physicians

The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Lipid Association designates this live activity for a maximum of 19.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 19 continuing professional education units (CPEUs) for completion of this program/ materials.

American Academy of Family Physicians

This Live activity, 2014 Annual Scientific Sessions, with a beginning date of 05/01/2014, has been reviewed and is acceptable for up to 18.50 Elective credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE credit provided by Postgraduate Institute for Medicine

Pharmacists

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Session I- Universal Activity Number 0809-9999-14-061-L01-P (Knowledge)

Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education

Session II- Universal Activity Number 0809-9999-14-062-L01-P (Knowledge)

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (.15 CEUs) of the Accreditation Council for Pharmacy Education

Session III – Universal Activity Number 0809-9999-14-063-L01-P (Knowledge)

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education

Session IV– Universal Activity Number 0809-9999-14-064-L01-P (Knowledge)

Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session V – Universal Activity Number 0809-9999-14-065-L01-P (Knowledge)

Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session VI – Universal Activity Number 0809-9999-14-066-L01-P (Knowledge)

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (.15 CEUs) of the Accreditation Council for Pharmacy Education

Session VII – Universal Activity Number 0809-9999-14-067-L01-P (Knowledge)

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education

Session VIII – Universal Activity Number 0809-9999-14-068-L01-P (Knowledge)

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education

Session IX – Universal Activity Number 0809-9999-14-069-L01-P (Knowledge)

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (.15 CEUs) of the Accreditation Council for Pharmacy Education

Session X – Universal Activity Number 0809-9999-14-070-L01-P (Knowledge)

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education

Session XI – Universal Activity Number 0809-9999-14-071-L01-P (Knowledge)

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education

Session XII – Universal Activity Number 0809-9999-14-072-L01-P (Knowledge)

Postgraduate Institute for Medicine designates this continuing education activity for 2.5 contact hour(s) (.25 CEUs) of the Accreditation Council for Pharmacy Education

Nursing

This educational activity for 17.9 contact hours is provided by the Postgraduate Institute for Medicine.

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Session I- 1.8 credits; Session II- 1.5 credits; Session III- 1.1 credits; Session IV- 2.0 credits; Session V- 2.0 credits; Session VI- 1.5 credits; Session VII- 1.2 credits; Session VIII- 1.0 credits; Session IX- 1.5 credits; Session X- 1.0 credits; Session XI- 0.9 credits; Session XII- 2.4 credits.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

 

 

Matthew K. Ito, PharmD, FCCP, CLS, FNLA

President, National Lipid Association
Professor of Pharmacy Practice
Oregon State University
Oregon Health and Science University
College of Pharmacy
Portland Campus at Oregon Health and Science University
Portland, OR

Ralph La Forge, MSc, FNLA, CLS

President, Southeast Lipid Association
Diplomate, Accreditation Council for Clinical Lipidology
Cardiometabolic Programing Consultants
Durham, NC

Terry A. Jacobson, MD, FNLA

President-Elect, National Lipid Association
Director, Office of Health Promotion and Disease Prevention
Professor of Medicine
Emory University
Atlanta, GA
Diplomate, American Board of Clinical Lipidology (ABCL)

Lori Alexander, MSHS, RD, CCRC, FNLA

President-Elect, Southeast Lipid Association
Site Manager
St. Johns Center for Clinical Research
Adjunct Professor
Masters in Nutrition Program
University of North Florida
Ponte Vedra, FL

Christie M. Ballantyne, MD, FNLA

Professor of Medicine
Professor of Genetics
Chief, Section of Cardiovascular Research
J.S. Abercrombie Chair- Atherosclerosis and Lipoprotein Research
Chief, Section of Cardiology
Department of Medicine
Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention
Director, The Maria and Alando J. Ballantyne, MD, Atherosclerosis Clinical Research Laboratory
Baylor College of Medicine and Methodist DeBakey Heart & Vascular Center
Diplomate, American Board of Clinical Lipidology (ABCL)

Vera A. Bittner, MD, MSPH, FNLA

Professor of Medicine
Section Head, Preventive Cardiology
University of Alabama at Birmingham
Birmingham, AL
Diplomate, American Board of Clinical Lipidology (ABCL)

William Virgil Brown, MD, FNLA

Charles Howard Candler Professor Emeritus
Emory University School of Medicine
Atlanta, GA
Diplomate, American Board of Clinical Lipidology (ABCL)

Matthew J. Budoff, MD, FACC

Professor of Medicine
David Geffen School of Medicine
Director of Cardiac CT
Harbor- UCLA Medical Center
Torrance, CA

Jerome D. Cohen, MD, FNLA

Emeritus Professor of Internal Medicine
Saint Louis University
School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology (ABCL)

Jonathan C. Cohen, PhD

Professor
Internal Medicine
Eugene McDermott Center for Human Growth & Development
UT Southwestern Medical Center
Dallas, TX

Joep C. Defesche, PhD

Department of Experimental Vascular Medicine
Academic Medical Center
Amsterdam, The Netherlands

P. Barton Duell, MD

Director of the Lipid Disorder Clinic
Director, Lipid-Atherosclerosis Laboratory
Oregon Health and Science University
Portland, OR

Mary N. Felando, RD, MS, CLS, FNLA

Nutrition Consultant
Rossmoor, CA

Anne C. Goldberg, MD, FNLA

Associate Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology (ABCL)

Scott Grundy, MD, PhD, FNLA

Professor,
University of Texas Southwestern Medical Center
Dallas, TX
Diplomate, American Board of Clinical Lipidology (ABCL)

Linda C. Hemphill, MD, FNLA

Instructor in Medicine
Harvard Medical School
Assistant Physician in Medicine
Massachusetts General Hospital
Boston, MA
Diplomate, American Board of Clinical Lipidology (ABCL)

Paul N. Hopkins, MD, MSPH

Professor of Internal Medicine
University of Utah
Salt Lake City, UT
Diplomate, American Board of Clinical Lipidology (ABCL)

Darwin R. Labarthe, MD, MPH, PhD

Professor of Preventive Medicine
Northwestern University Feinberg School of Medicine
Department of Preventive Medicine
Chicago, IL

Brian W. McCrindle, MD, MPH

Department of Pediatrics
University of Toronto
The Hospital for Sick Children
Toronto, Ontario, Canada

James M. McKenney, PharmD, FNLA

President and CEO
National Clinical Research
Professor Emeritus
Virginia Commonwealth University
Richmond, VA

Patrick M. Moriarty, MD, FNLA

Professor, Department of Internal Medicine
Director, Division of Clinical Pharmacology and
Atherosclerosis/ Lipid Apheresis Center
University of Kansas Medical Center
Kansas City, KS

Pamela B. Morris, MD, FACC, FACP, FACPM, FAHA, FNLA

Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Charleston, SC
Diplomate, American Board of Clinical Lipidology (ABCL)

Carl E. Orringer, MD, FACC, FNLA

Associate Professor of Medicine (Pending Rank)
University of Miami
School of Medicine
Miami, FL
Diplomate, American Board of Clinical Lipidology (ABCL)

Joyce L. Ross, MSN, ANP, CLS, CRNP, FPCNA, FNLA

President- Elect, Northeast Lipid Association
President, Preventive Cardiovascular Nurses Association
Consultative Education Specialis, Cardiovascular Risk Intervention
University of Pennsylvania Health System- Retired
Philadelphia, PA

Raul D. Santos, MD, PhD

Director, Lipid Clinic of the Heart Institute (InCor)
University of São Paulo, Brazil
Associate Professor
Discipline of cardiology
University of São Paulo Medical School
São Paulo, Brazil

Michael D. Shapiro, DO, FACC, FSCCT

Assistant Professor of Medicine and Radiology
Director, Cardiac MR and CT
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology (ABCL)

Neil J. Stone, MD, MACP, FAHA, FACC, FNLA

Bonow Professor of Medicine
Feinberg School of Medicine
Northwestern University
Suzanne and Milton Davidson Distinguished
Physician and Medical Director, Vascular Center of the Bluhm Cardiovascular Institute of Northwestern Memorial Hospital
Chicago, IL
Diplomate, American Board of Clinical Lipidology (ABCL)

 

Amy Sturm, MS, LGC

Licensed Genetic Counselor
Associate Professor
Internal Medicine
Cardiovascular Genetic Medicine Program
Division of Human Genetics
Ohio State University Wexner Medical Center
Columbus, OH

Allen J. Taylor, MD, FACC, FAHA

Chief, Cardiology Division
Medstar Heart Institute
Washington, DC

Paul D. Thompson, MD

Chief of Cardiology
Hartford Hospital
Hartford, CT

James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA

President, Northeast Lipid Association
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
New York, NY
Diplomate, American Board of Clinical Lipidology (ABCL)

Gerald F. Watts, DSc, PhD, MD, FRACP, FRCP

Winthrop Professor
Cardiometabolic Medicine
University of Western Australia
Perth, Western Australia

Paul E. Ziajka, MD, PhD, FNLA

Director, Florida Lipid Institute
Winter Park, FL
Diplomate, American Board of Clinical Lipidology (ABCL)

Early-Bird Registration has been extended to March 31, 2014! Register Now to save $75

We can pre-fill much of this information for you if you are a member and login first. If you are a member; but have not yet setup your web account, or cannot remember your username and password, try writing the webmaster first.

NLA Offers a substantial meeting registration discount to Members. If you would like to join the NLA at $100 annually, please click here.

Ancillary Courses includes:

 

Registration Discount Disclaimer
Discount codes cannot be retroactively applied to existing meeting registrations. The meeting discount codes are applicable to new registrants only.

*Registration and payment must be received no later than April 1, 2014. After this date a syllabus and name badge cannot be guaranteed.

Cancellation: Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than April 1, 2014. This includes social events and guest fees. There will be a $25 fee for all cancellations.

*Must be logged in to see discounted NLA member rate. If you are not logged in, please use your credentials to log in at the top of the page.

Plan now for your company to participate in the National Lipid Association’s premier scientific meeting series in 2014. Our meetings provide you with a unique opportunity to reach our target audience of Lipidologists, Cardiologists, Endocrinologists, Primary Care Physicians and Allied Health Professionals involved in dyslipidemia management, as well as our distinguished board and faculty.

Our numerous sponsorship opportunities allow you to connect with our members in a whole new way, providing you with maximum return on your investment. The exhibit hall provides a unique setting for you and your company’s representatives to interact daily with attendees as they study the latest advances in their professions. Exhibiting is an excellent way to showcase your commitment to the NLA. You may take these opportunities to acquaint the attendees with the benefits of your products and services in an intimate setting.

If you are interested in becoming a grant supporter or have any questions regarding exhibit opportunities, please contact the Event Department directly, contact info below.

The Annual Scientific Sessions Exhibit Prospectus

 

 

You also can download: The Fall Clinical Lipid Update Exhibit Prospectus (Indianapolis, IN).

 

 

Contact Info:
Theresa Henson
Event Coordinator
904-309-6207
thenson@lipid.org

 

Acasti Pharma
Acasti Pharma is a biopharmaceutical dedicated to R&D and commercialization of innovative proprietary APIs for the management of cardio metabolic disorders through novel superior approach with prescription drugs and medical foods.

ACCUSPLIT, Inc.
Certified accurate pedometers and activity wellness programs are helping American’s walk to wellness. Stop by and see the new Accelerometer Pedometer. Accurate even worn at a tilt!

Aegerion
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases. The company is based in Cambridge, Massachusetts and has an established international presence.

Amarin Pharma Inc.
Amarin Pharma Inc. is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's first FDA approved product is available in the United States by prescription.

Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Atherotech
Atherotech's proprietary VAP® Lipid Panel enables clinicians to accurately stratify a patient’s risk and deliver personalized treatment to improve health outcomes.

B. Braun Medical Inc.
The H.E.L.P. (Heparin-induced Extracorporeal Lipoprotein Precipitation) System provided in the U.S. by B. Braun Medical is a proven procedure, known as LDL Apheresis, which selectively removes low density lipoproteins for the treatment of severe cholesterolemia. Stop by the B. Braun booth to see the Plasmat® Futura Treatment System. For additional information, please call 800-848-2066.

Carlson Laboratories
Carlson Laboratories began with a single vitamin E formula. Since then, it has grown to become the world’s most complete line of natural-source vitamin E products. Our product range has expanded and includes award-winning Norwegian fish oils, a full line of vitamins, minerals, amino acids, special formulations and other supplements.

Cleveland Heartlab, Inc.
Cleveland HeartLab, Inc. is a premier, next-generation clinical reference laboratory committed to advancing cardiovascular risk assessment through unique and proprietary diagnostic tests. We focus on novel inflammatory and cardiovascular biomarker technologies that allow for personalized treatment recommendations.

DiaDexus
diaDexus, Inc., based in South San Francisco California, USA develops and commercializes proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. The diaDexus PLAC® Test is a simple blood test that measures Lp-PLA2, a vascular-specific inflammatory marker critical in the formation of rupture-prone plaque. Visit www.plactest.com for more information.

DuPont
DuPont Nutrition & Health addresses the world's challenges in food by offering a wide range of ingredients to provide healthier and more nutritious food.

Endurance Products Company
Endurance Products Company (EPC) , is the exclusive marketing affiliate of Innovite Inc, manufacturer of select nutritional supplements which feature the proprietary wax-matrix, controlled-release technology. Endur-acin® is our best-selling, extended-release nicotinic acid, which has consistently demonstrated good clinical results and unsurpassed patient tolerability in controlled clinical studies.

The Foundation for Health Improvement and Technology (FHIT)
The Foundation for Health Improvement and Technology (FHIT) is dedicated to worldwide, high-level education of physicians and other clinical and laboratory professionals on the widespread utility of biomarkers in cardiometabolic disease prevention and treatment through early and accurate risk assessment, therapeutic guidance and goals.

Genzyme - A Sanofi Company
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with approximately 10,000 employees in locations spanning the globe and 2009 revenues of $4.5 billion.

Health Diagnostic Laboratory, Inc.
Health Diagnostic Laboratory, Inc. (HDL, Inc.) is a leader in health management offering a comprehensive test menu of risk factors and biomarkers for cardiovascular disease, diabetes, and related diseases. HDL, Inc.’s systematic approach identifies factors contributing to disease and can provide a basis for personalized treatment, allowing physicians to more effectively manage patients. Individuals receive a personalized overview of their risk factors along with intensive counseling from expert Clinical Health Consultants at no additional cost, improving compliance and enhancing satisfaction. HDL, Inc. is a CLIA-certified, CAP-accredited laboratory.

Lipoprotein(a) Foundation
The mission of the Lipoprotein(a) Foundation is to prevent cardiovascular events due to high Lipoprotein(a) by revealing this inherited risk for cardiovascular disease, empowering patients and saving lives. Our goal is to save lives by increasing awareness, advocating for routine testing, and a specific treatment for high Lipoprotein(a). It is estimated that 1 in 5 Americans have high Lipoprotein(a) and are at risk of premature cardiovascular disease.

Kaneka Pharma America LLC
There is hope for your patients with hypercholesterolemia!
LIPOSORBER® LDL Apheresis
Beyond Diet and Drug Therapy
For Acute Lowering of LDL-C 73%-83%

Kowa Company, Ltd.
Kowa Company, Ltd. (Kowa) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and trading activities in the fields of pharmaceuticals, life science, information technology, textiles, machinery and various consumer products. Kowa's pharmaceutical division is focused on cardiovascular therapeutics, and the company’s flagship product, LIVALO® (pitavastatin) was launched in the United States in June 2010. For more information about Kowa Pharmaceuticals America, visit www.kowapharma.com.

LipoScience
LipoScience Inc, offers the NMR LipoProfile® test, the only FDA-cleared blood test that directly quantifies LDL particles. LDL-P by NMR is a more clinically reliable measure of LDL used to manage patients with increased CVD risk.

Merck
Today's Merck is a global healthcare leader working to help the world be well.

ReachMD
ReachMD is an award-winning producer and distributor of healthcare information and education for medical professionals nationwide. Leveraging first-to-market, proprietary broadcast technologies to deliver compelling digital content across multiple platforms. ReachMD programs broadcast 24/7 on iHeart Radio and TuneIn Radio channels, streamed simulcast on ReachMD.com, and offered on-demand through free mobile apps.

Sanofi and Regeneron
Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients' needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.

Step-One Foods
Co-founded by a practicing cardiologist, Step One Foods produces convenient foods for heart health that contain scientifically-proven levels of phytosterols, Omega 3s, antioxidants, and fiber.

Synageva
Synageva BioPharma Corporation is a biopharmaceutical company working to deliver breakthrough medicines globally for patients suffering from rare, devastating diseases. Our lead program, sebelipase alfa (SBC-102), is a recombinant human enzyme replacement therapy for Lysosomal Acid Lipase Deficiency (LAL D), a lysosomal storage disorder (LSD).

Foundation Events:

Dinner, Dancing & Games Galore

Saturday, May 3 | 7:30 – 10:00 p.m.
Cocktails 7:30 – Dinner 8:00 – Games 9:00*
$150 per person

Join the Foundation of the NLA for a fun evening of dinner, dancing and games galore.
Enjoy the perfect backdrop of the lush tropical landscaping and a free-flowing lagoon pool** with 12 picturesque waterfalls. It is the perfect setting to enjoy a scrumptious buffet meal. Dance under the stars to music of the 50s, 60s, and 70s or grab some friends or colleagues for a friendly game of Giant Jenga or Connect Four that will be available for your enjoyment.

*If you would like to attend the Games portion of the event only after 9:00 p.m., cost is $75 per person; cash bar available.
**Location may change depending on weather.

 

Golf Tournament

Sunday, May 4 | 8:00 a.m.***
$95 per person

Sign up for a golf tournament at one of the Hyatt Regency Cypress Hotel golf courses to support the Foundation of the NLA. Enjoy the new 18-hole course, reminiscent of the Old Course at St. Andrews, complete with 12-foot pot bunkers, stone walls and more.

You may sign up as a foursome or individually. To reserve your spot register by April 18.

***This event will be cancelled if less than four people register by April 18 or in the case of inclement weather.

 

Special Events:

Honors & Awards Ceremony

Saturday, May 3 | 6:30 – 7:30 p.m.

The National Lipid Association, in cooperation with the certification bodies of the American Board of Clinical Lipidology (ABCL) and the Accreditation Council for Clinical Lipidology (ACCL) will host its annual Honors and Awards Ceremony.

The ABCL and ACCL will recognize the achievements of those who successfully passed the ABCL or Clinical Lipid Specialist (CLS) exams. The NLA will also present the Distinguished Achievement Award, the Honorary Lifetime Member Award, and the President’s Service Award, as well as induct the 2014 class of Fellows of the NLA.

 

Non-CME Workshop

An Invitation to Publish in the Journal of Clinical Lipidology

Sunday, May 4 | 8:00 – 9:00 a.m.

Host:
W. Virgil Brown, MD, FNLA
Charles Howard Candler Professor Emeritus
Emory University School of Medicine
Atlanta, GA
Diplomate, American Board of Clinical Lipidologyy

During the National Lipid Association Annual Scientific Sessions May 1–4 in Orlando, Dr. Virgil Brown will be on hand for a non-CME session on tips for getting your paper published in the Journal. To find out more about this session and to register, visit lipid.org/sessions. There is no cost to register for this non-CME Symposium and you may indicate your interest in participating on the registration form.

 

Poster Sessions

Presentation Methods
In addition to posters being displayed at the meeting, selected abstract submissions will be identified for a live oral presentation session. The NLA Abstract Review Committee will select three abstracts to be presented during a designated session on the meeting program. Authors will have 8−10 minutes to present their research, with three minutes to follow for questions and answers.

Travel Grants and Awards
NLA Young Investigator Awards
Sponsored by LipoScience, Inc. Lead presenters with accepted abstracts who are Young Investigators (in-training students, residents and fellows or members in practice for < 5 years) will have the chance to compete for the NLA’s enhanced Young Investigator Award offering a $1,000 cash prize and certificate to first place and a $500 cash prize to second and third place. The award winners will receive recognition at a special ceremony on Friday, May 2, 2014. In addition, the first place winner will present his/her abstract during the live oral presentation session and have the poster printed in the LipidSpin following the meeting.

Friday, May 2 | 12:35 – 1:35 p.m.
Young Investigator Awards & Oral Presentations

Thursday May 1, 2014

New Avenues in the Management of Hypertriglyceridemia

Severe hypertriglyceridemia can be related to a variety of genetic defects.  These are rare diseases and little is known about the epidemiology and the natural history of disease. Findings from a patient claims database suggest that lipid management and pancreatitis are major challenges for patients with high triglyceride levels. In Canada, there is a founder population of patients with familial chylomicronemia and lessons can be learned from the experiences gained in treating these patients.  There are no approved therapies.  There are new emerging therapies on the horizon.  A case study will highlight the complexity of the disease. A patient centric registry has been initiated where patients can share the history of the disease to help better define familial chylomicronemia and the natural history of disease. 

When: 7:00 - 9:00 PM

Faculty:
Daniel Gaudet, MD, Chair
Ira Goldberg, MD
Peter Toth, MD
James Underberg, MD

Location: Grand Cypress Ballroom ABC at the Hyatt Regency Grand Cypress Hotel in Orlando, FL

Register here to ensure meeting materials and space!

Brought to you by Novartis Pharmaceuticals
 
This event is not part of the official National Lipid Association Scientific Sessions, as planned by the NLA Education Committee, and is not being certified for CME/CE credit
 

Friday May 2, 2014

Integrating Obesity and Dyslipidemia Management To Reduce Atherosclerotic Disease

This innovative CME/CE Dinner Symposium will showcase acclaimed expert educators addressing the complex interrelationship of obesity and dyslipidemia in a highly engaging, case-based format.

When: 7:00 - 9:30 PM

Faculty:
Harold E. Bays, MD, FTOS, FACE, FNLA, Chair
Daniel H. Bessesen, MD
Eliot A. Brinton, MD, FAHA, FNLA

Location: Grand Cypress Ballroom ABC at the Hyatt Regency Grand Cypress Hotel in Orlando, FL

Register here to ensure meeting materials and space!

Brought to you by Amarin Pharma Inc., VIVUS Inc., and Medtelligence, LLC.

This activity is jointly provided by the National Lipid Association.

 
 

Saturday May 3, 2014

Mystery Cases of Genetic Dyslipidemia

When: 6:30 - 7:45 AM

Faculty:
W. Virgil Brown, MD, Chair
Nirav Desai, MD
Don Wilson, MD
Michael Shapiro, MD

Location: Grand Cypress Ballroom ABC at the Hyatt Regency Grand Cypress Hotel in Orlando, FL

Registration information coming soon

Brought to you by Synageva BioPharma Corp.

This event is not part of the official National Lipid Association Scientific Sessions, as planned by the NLA Education Committee, and is not being certified for CME/CE credit.

2014 SATELLITE SYMPOSIA GUIDELINES

The National Lipid Association (NLA) has established that independently developed and CME/CE certified satellite symposia held in conjunction with the scientific meetings of the NLA are valuable opportunities to provide continuing education for our members. In this regard, we are pleased to offer satellite symposia slots in conjunction with our 2014 NLA Meeting Series.
 
Satellite symposia are non-commercial CME- and CE-certified activities addressing educational needs and performance gaps that complement the NLA scientific program agenda. They may include one or a number of speakers and may cover one or several topics addressing the educational gaps of lipid specialists.
 
The following deadlines and guidelines provide important information about holding a
satellite symposium at an NLA meeting and the process for completing a symposium proposal. Please contact the NLA business development department directly (contact below) should there be any questions or further information required. See you in 2014!
 

DOWNLOAD SATELLITE SYMPOSIA GUIDELINES 2014

 

 

Contact:
Amina Resheidat
Program Coordinator
904-309-6212

aresheidat@lipid.org

0
No votes yet

Saturday, March 15
 
Workshop 1: Lipids on the Front Lines
12:45 - 1:15 PM Interpreting results: is There a Role for Advanced Lipid Testing? Elizabeth J. Jackson, MSN, CNS, CLS, FNLA
1:15 - 1:45 PM Navigating Around the Roadblocks: Lipid Management, Barriers and Byways Randy W. Burden, PharmD, MDiv, PhC, CLS, FNLA
1:45 - 2:15 PM Cardiometabolic Benefits of Low - Intensity Physical Activity Marc Hamilton, PhD
2:15 - 2:45 PM Case Study Wrap Up and Q&A  

 

Workshop 2: Lipid Science and Research
12:45 - 1:15 PM How do we Avoid Faltering in Design of Clinical Trials? Eliot Brinton, MD, FNLA*
1:15 - 1:45 PM Should we Change the Endpoints in Cardiovascular Research Outcomes? Sekar Kathiresan, MD
1:45 - 2:15 PM Framingham and Beyond: Lessons Learned and Future Needs from Key Epidemiologic Studies Nathan D. Wong, PhD
2:15 - 2:45 PM Case Study Wrap Up and Q&A  

 

Please select one workshop. Workshop included in your registration.

Monoclonal Antibodies (mAbs): Three Decades of Innovation and Progress

 
When:
May 2, 2014 at 12:00-1:00PM

 
Faculty:

Eli M. Roth MD, FACC, FNLA

Medical Director, Sterling Research Group

Professor of Clinical Medicine, University of Cincinnati

 
Where:
Grand Cypress Ballroom G

 

Brought to you by Sanofi-aventis U.S. and Regeneron Pharmaceuticals, Inc.

0
No votes yet



by Dr. Radut.